Specialty hub

Rheumatology

Containing dedicated Learning Zones, guidelines, trials and news for related conditions in Rheumatology.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Rheumatology is branch of medicine that deals with the diagnosis and treatment of disorders of connective tissues and joints, many of which are now known to be immune mediated conditions.

Featured Learning Zones

Learning Zone Homepage

Managing Osteoarthritis-associated Pain

Did you know that treating pain in osteoarthritis (OA) is changing? Discover the burden of OA, emerging therapies and personalised pain management.

Learning Zone Homepage

Optimising anti-TNF treatment using biosimilars

Biosimilars are uniquely placed to change clinical practice in the fields of gastroenterology, rheumatology, and dermatology. The adoption of biosimilars can improve patient access to the most appropriate treatment, at the optimum time, to ensure the best possible long-term disease outcomes.

Rheumatic diseases can be caused by trauma, heredity, genetic abnormality, autoimmune disease, or another underlying condition such as cancer. There are more than 150 different types of rheumatic disorders, including arthritis, rheumatoid and osteoarthritis, gout and lupus.

Diseases in this section

Arthritis

Containing relevant Learning Zones, guidelines, trials and news.

Osteoarthritis

Containing relevant Learning Zones, guidelines, trials and news.

Lupus

Containing relevant Learning Zones, guidelines, trials and news.

Related news and insights

News

Skyrizi filed with FDA and EU for psoriatic arthritis.- AbbVie

AbbVie announced that it has submitted applications seeking approval for Skyrizi (risankizumab-rzaa, 150 mg) to the U.S. Food and Drug Administration (FDA) and for Skyrizi (risankizumab, 150 mg) to the European Medicines Agency (EMA) for the treatment of adults with active psoriatic arthritis.

1 mins

News

Phase III SELECT-PsA 1 trial of Rinvoq in psoriatic arthritis published in NEJM.- AbbVie

AbbVie announced that the New England Journal of Medicine has published 24-week results from the Phase III SELECT-PsA 1 trial evaluating Rinvoq (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs).

1 min

News

Joint FDA advisory committee votes against application for tanezumab for the treatment of osteoarthritis pain.- Eli Lilly + Pfizer

Pfizer Inc. and Eli Lilly and Company announced the outcome of the FDA Joint Arthritis Advisory Committee and Drug Safety and Risk Management Advisory Committee on tanezumab. There was a single voting question focused on whether the proposed risk evaluation and mitigation strategy (REMS) for tanezumab will ensure its benefits outweigh its risks, and the Committee voted 1 in favor and 19 against.

1 min

See all news

Related Drugs

Ruxience 100 mg concentrate for solution for infusion, Ruxience 500 mg concentrate for solution for infusion

99 mins

Valket 200 Retard (Ketoprofen 200mg Controlled Release Capsules)

12 mins

Voltarol Osteoarthritis Joint Pain Relief 1.16% Gel

8 mins

Voltarol Medicated Plaster

8 mins

Voltarol 12 Hour Joint Pain Relief 2.32% Gel

10 mins

Movelat Gel/ Movelat Relief Gel

4 mins

Movelat Cream/Movelat Relief Cream

4 mins

Cimzia 200 mg solution for injection in pre-filled syringe

61 mins

Cimzia 200 mg solution for injection in pre-filled pen

57 mins

Cimzia 200 mg solution for injection in dose-dispenser cartridge

57 mins

Celecoxib 200mg hard capsules

27 mins

Celecoxib 200mg Capsules, hard

26 mins

Celecoxib 200mg capsules

25 mins

Celecoxib 200 mg, capsule, hard

27 mins

Celecoxib 200 mg capsules, hard

26 mins

Related Journals

Journal

Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2

3 mins

Journal

Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials

1 mins

Journal

Diagnostic value of TWEAK for predicting active lupus nephritis in patients with systemic lupus erythematosus: a systematic review and meta-analysis

1 mins

Journal

The Association between Interleukin-6 Gene Polymorphisms and Risk of Systemic Lupus Erythematosus: A Meta-analysis with Trial Sequential Analysis

1 mins

Journal

Low-dose glucocorticoid should be withdrawn or continued in systemic lupus erythematosus? A systematic review and meta-analysis on risk of flare and damage accrual

1 mins

Journal

The risk of infections in adult patients with systemic lupus erythematosus: systematic review and meta-analysis

1 mins

Journal

Risk factors for mortality of diffuse alveolar hemorrhage in systemic lupus erythematosus: a systematic review and meta-analysis

1 mins

Journal

Maternal and fetal complications associated with systemic lupus erythematosus: An updated meta-analysis of the most recent studies (2017-2019)

1 mins

Journal

Systematic review and meta-analysis of HPV vaccination in women with systemic lupus erythematosus (SLE)

1 mins

Journal

Association of systemic lupus erythematosus with hearing loss: a systemic review and meta-analysis

1 mins

Related Guidelines

Guideline

2019 update of the EULAR recommendations for the management of systemic lupus erythematosus

The updated recommendations provide physicians and patients with updated consensus guidance on the management of SLE, combining evidence-base and expert-opinion.

1 mins

Guideline

NRAS position paper on biosimilar medicines Updated February, 2019

In this position paper we set out our recommendations for a national best practice approach to be taken.

1 min

Guideline

EULAR recommendations for the use of imaging in the clinical management of peripheral joint osteoarthritis

These evidence-based recommendations and related research agenda provide the basis for sensible use of imaging in routine clinical assessment of people with OA.

1 min

See all guidelines